1. Home
  2. SCPQ vs RCEL Comparison

SCPQ vs RCEL Comparison

Compare SCPQ & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCPQ

Social Commerce Partners Corporation Class A Ordinary Shares

N/A

Current Price

$9.96

Market Cap

135.5M

Sector

N/A

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.18

Market Cap

129.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCPQ
RCEL
Founded
2025
N/A
Country
United States
United States
Employees
2
226
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
129.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCPQ
RCEL
Price
$9.96
$4.18
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
755.0
265.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.86
$3.22
52 Week High
$10.00
$7.12

Technical Indicators

Market Signals
Indicator
SCPQ
RCEL
Relative Strength Index (RSI) 62.90 46.29
Support Level $9.89 $4.00
Resistance Level N/A $4.57
Average True Range (ATR) 0.01 0.33
MACD 0.00 -0.01
Stochastic Oscillator 66.67 29.03

Price Performance

Historical Comparison
SCPQ
RCEL

About SCPQ Social Commerce Partners Corporation Class A Ordinary Shares

Social Commerce Partners Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: